(Q35782940)

10 August 2017

1 reference

title

Novel therapies for recurrent ovarian cancer management (English)

1 reference

10 August 2017

1 reference

Snehal M Bhoola

1

1 reference

10 August 2017

Ronald D Alvarez

series ordinal

2

1 reference

10 August 2017

publication date

1 June 2004

1 reference

Expert Review of Anticancer Therapy

10 August 2017

published in

1 reference

10 August 2017

volume

4

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

437-448

1 reference

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.437

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.437

Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.437

Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.437

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.437

Intraperitoneal immunotherapy for ovarian cancer with alpha interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.437

Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.437

Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.437

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.437

Biologic and Immunologic Therapies for Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.437

Ovarian cancer gene therapy: repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.437

Adenoviral-mediated suicide gene therapy for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.437

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.437

Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.3.437

21 January 2018

Identifiers

DOI

10.1586/14737140.4.3.437

1 reference

10 August 2017

1 reference